China healthcare-focused GP C-Bridge Capital and Tasly Holding, a traditional Chinese medicine business, have agreed to invest $150 million in a newly-created entity formed through the merger of two local pharmaceutical companies.
Eight Roads decided to leverage the development of China’s healthcare sector by building a hospital, but addressing the various challenges that come with a greenfield strategy requires very patient capital
Suzhou Ribo Life Science, a Chinese drug developer that focuses on liver diseases, has raised a RMB270 million ($40 million) Series B round led by SDIC Fund Management.
TA Associates has invested in Indian pharmaceutical product supplier Ideal Cures. Neither the size of the commitment nor the size of the GP's stake in the company were disclosed.
The Innovation Network Corporation of Japan (INCJ) has teamed up with two pharmaceutical players to invest JPY10 billion ($87 million) in the creation of a biotech spin-out. INCJ will hold a 70.5% stake in the company.
Healthcare-focused PE investor Ally Bridge Group will support the HK$2.3 billion ($301 million) management-led take-private of Hong Kong-listed Shandong Luoxin Pharmacy Group.
Singapore’s EDBI and Philips have formally launched an Asia-focused investment platform that targets companies in digital healthcare services.
Integrated Healthcare Holdings (IHH), which is majority-owned by Malaysian sovereign wealth fund Khazanah Nasional, has sold part of its stake in India's Apollo Hospitals for INR10.7 billion ($160 million).
Hospital Corporation of China (HCC), a hospital operation group established by Hony Capital, has launched a Hong Kong IPO that would see the company raise as much as HK$500 million ($64 million).
Indian healthcare testing firm iGenetic Diagnostics has raised INR1.3 billion ($19.9 million) from UK-based development finance institution (DFI) CDC Group and Indian conglomerate Manipal Education & Medical Group.
Beijing-based Anxin Doctor, a mobile app focused on pediatric and women's healthcare, has completed a RMB200 million ($29 million) Series B round of funding across two tranches.
The International Finance Corporation (IFC), the investment arm of the World Bank, has proposed a commitment of $60 million to IDS Medical Systems, a Hong Kong-based healthcare industry supplier for Southeast Asia.
UK-based development finance institution (DFI) CDC Group has partnered with India’s Manipal Education & Medical Group for an $80 million fund targeting healthcare investments in emerging markets.
Judith Li, a partner with Lilly Asia Ventures, discusses healthcare investment opportunities in China
US-based venture capital firm Unitus Impact has led a $6.5 million Series A funding round for Singaporean healthcare technology start-up mClinica.
AGIC Capital is targeting up to three more deals in 2017 as its debut Asia-Europe fund closes at $1 billion, having received strong support from Asian LPs
Chinese private equity firm HG Capital has led a RMB160 million ($23 million) round of funding for Beijing Nuokangda Pharmaceutical Technology, a contract research organization (CRO).
Accel Partners has led a $5.8 million Series A round for Indian healthcare-focused AI start-up SigTuple Technologies.
Indian pharmaceutical company Eris Lifesciences has filed for a domestic IPO that is expected to facilitate a full exit for ChrysCapital Partners, which has been an investor since 2011.
Japan-based investor Beyond Next Ventures has led a JPY380 million ($3.4 million) round for domestic healthcare software developer CureApp.
Yaoshibang, a Chinese B2B pharmaceutical trading platform, has raised a RMB110 million ($16 million) Series B round co-led by Shenzhen-based Green Pine Capital Partners and Fosun Group.
The investment arm of Singapore's Economic Development Board (EDBI) and B Capital Group have led a $25 million Series B funding round for Singaporean health technology start-up CXA Group.
German healthcare services and equipment provider Fresenius Medical Care has agreed to take control of Australia’s Cura Group, a hospital operator backed by Intermediate Capital Group (ICG).
Qiming Venture Partners has led a $20 million Series A round of funding for Chinese drug developer Connect Biopharmaceuticals.